Piper Jaffray & Co. upgrades Myriad Pharmaceuticals (Nasdaq: MYRX) from Underweight to Neutral. Price target increased from $3.50 to $5.00 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE